• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Is Vaccine Maker Emergent BioSolutions Stock Trading Higher On Tuesday?

    7/2/24 12:53:06 PM ET
    $EBS
    $NVDA
    $TSM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Semiconductors
    Technology
    Get the next $EBS alert in real time by email

    Nvidia Corp (NASDAQ:NVDA) is trading lower Tuesday amid reports that the company faces antitrust charges from French regulators.

    These charges follow dawn raids conducted last September, which resulted in formal objections and a charge sheet against Nvidia.

    Meanwhile, on a positive note, Nvidia supplier Taiwan Semiconductor Manufacturing Co (NYSE:TSM) plans to significantly boost its capital expenditures in 2025 due to high demand and progress in its 2nm technology. Industry reports indicate TSMC's capital spending will rise between $32 billion and $36 billion.

    Nvidia has more reasons to be happy as the Biden administration announced a $504 million funding package to support 12 regional technology hubs across the U.S.

    The funds provided by the Department of Commerce aim to boost research in AI, semiconductor manufacturing, and clean energy.

    Recipients include technology hubs in New York, Florida, Nevada, and South Carolina, and benefits will also be extended to parts of Georgia.

    Analysts have praised Nvidia, citing robust demand for its Hopper builds. They expect continued strength as the H100 transitions to the H200.

    Nvidia shares gained 188% in the last 12 months. Investors can gain exposure to the stock via Vanguard Total Stock Market ETF (NYSE:VTI) and SPDR Select Sector Fund – Technology (NYSE:XLK).

    NVDA Price Action: Nvidia shares traded lower by 1.84% to $122.02 at the last check Tuesday.

    Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

    Photo via Unsplash

    Get the next $EBS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EBS
    $NVDA
    $TSM

    CompanyDatePrice TargetRatingAnalyst
    Taiwan Semiconductor Manufacturing Company Ltd.
    $TSM
    2/13/2026$450.00Buy
    DA Davidson
    NVIDIA Corporation
    $NVDA
    1/15/2026$240.00Outperform
    RBC Capital Mkts
    Taiwan Semiconductor Manufacturing Company Ltd.
    $TSM
    1/15/2026$360.00 → $410.00Buy
    Needham
    Taiwan Semiconductor Manufacturing Company Ltd.
    $TSM
    12/8/2025$290.00 → $330.00Outperform
    Bernstein
    NVIDIA Corporation
    $NVDA
    11/21/2025$272.00Strong Buy
    Raymond James
    NVIDIA Corporation
    $NVDA
    11/20/2025$225.00 → $275.00Outperform
    Robert W. Baird
    NVIDIA Corporation
    $NVDA
    11/20/2025$240.00 → $250.00Buy
    Jefferies
    NVIDIA Corporation
    $NVDA
    11/20/2025$220.00 → $250.00Buy
    The Benchmark Company
    More analyst ratings

    $EBS
    $NVDA
    $TSM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Papa Joseph C bought $349,800 worth of shares (60,000 units at $5.83), increasing direct ownership by 21% to 342,500 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    5/15/25 4:02:40 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    $NVDA
    $TSM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    DA Davidson initiated coverage on Taiwan Semiconductor Manufacturing with a new price target

    DA Davidson initiated coverage of Taiwan Semiconductor Manufacturing with a rating of Buy and set a new price target of $450.00

    2/13/26 8:32:20 AM ET
    $TSM
    Semiconductors
    Technology

    RBC Capital Mkts initiated coverage on NVIDIA with a new price target

    RBC Capital Mkts initiated coverage of NVIDIA with a rating of Outperform and set a new price target of $240.00

    1/15/26 8:38:56 AM ET
    $NVDA
    Semiconductors
    Technology

    Needham reiterated coverage on Taiwan Semiconductor Manufacturing with a new price target

    Needham reiterated coverage of Taiwan Semiconductor Manufacturing with a rating of Buy and set a new price target of $410.00 from $360.00 previously

    1/15/26 7:51:54 AM ET
    $TSM
    Semiconductors
    Technology

    $EBS
    $NVDA
    $TSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, General Counsel, Corp Sec Perl Jessica covered exercise/tax liability with 918 shares, decreasing direct ownership by 1% to 67,469 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    2/10/26 7:11:20 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Quality & Ethics, and CPL Glessner Coleen returned $315,009 worth of shares to the company (28,847 units at $10.92) and covered exercise/tax liability with 2,852 shares, decreasing direct ownership by 22% to 112,620 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    2/10/26 7:09:25 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Products Business Williams Paul Anthony returned $94,513 worth of shares to the company (8,655 units at $10.92) and covered exercise/tax liability with 1,022 shares, decreasing direct ownership by 11% to 76,194 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    2/10/26 7:07:24 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    $NVDA
    $TSM
    SEC Filings

    View All

    SEC Form 6-K filed by Taiwan Semiconductor Manufacturing Company Ltd.

    6-K - TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD (0001046179) (Filer)

    2/10/26 7:34:25 AM ET
    $TSM
    Semiconductors
    Technology

    SEC Form 6-K filed by Taiwan Semiconductor Manufacturing Company Ltd.

    6-K - TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD (0001046179) (Filer)

    2/10/26 7:09:45 AM ET
    $TSM
    Semiconductors
    Technology

    SEC Form 6-K filed by Taiwan Semiconductor Manufacturing Company Ltd.

    6-K - TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD (0001046179) (Filer)

    2/10/26 7:00:18 AM ET
    $TSM
    Semiconductors
    Technology

    $EBS
    $NVDA
    $TSM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks

    Approval will broaden the NARCAN® Nasal Spray portfolio, and improve cost-effectiveness by increasing flexibility and distribution efficiency of this life-saving medication  GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions (NYSE:EBS) announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for new multipack configurations of over-the-counter (OTC) NARCAN® Nasal Spray. This approval expands the NARCAN® Nasal Spray product suite to include 6-count and 24-count multipack options, specifically designed to meet the needs of partners distributing higher volumes of naloxone. These new formats offer enhan

    2/12/26 6:00:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year of 2025. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of

    2/12/26 9:02:20 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dassault Systèmes and NVIDIA Partner to Build Industrial AI Platform Powering Virtual Twins

    Shared industrial AI architecture combines Virtual Twins and AI infrastructure deployable at scale. Science-validated world models position industrial AI as a mission-critical system of record, not a point solution. Platform accelerated by NVIDIA, grounded in science by Dassault Systèmes, expands long-term value creation across biology, materials science, engineering and manufacturing through a new way of working: skilled virtual companions. Dassault Systèmes (PARIS:FR, DSY.PA)) and NVIDIA today announced a long-term strategic partnership to establish a shared industrial architecture for mission-critical artificial intelligence across industries. This press release features multi

    2/3/26 11:00:00 AM ET
    $NVDA
    Semiconductors
    Technology

    $EBS
    $NVDA
    $TSM
    Leadership Updates

    Live Leadership Updates

    View All

    Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors

    GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) announced today that Dr. Louis W. Sullivan will retire from the company's Board of Directors effective November 14 after 19 years of service to the company and its shareholders. "For nearly two decades, Dr. Sullivan has been a trusted advisor and champion of Emergent's mission to protect and save lives," said Joe Papa, president and CEO of Emergent. "On behalf of the Board and the entire Emergent team, I want to thank him for his distinguished leadership and contributions. We wish him all the best." Dr. Sullivan served on Emergent's Board of Directors since 2006, and most recently served as chair of the

    11/12/25 4:01:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palantir and NVIDIA Team Up to Operationalize AI — Turning Enterprise Data Into Dynamic Decision Intelligence

    News Summary Palantir is integrating NVIDIA accelerated computing, NVIDIA CUDA-X libraries and open-source NVIDIA Nemotron models into its Ontology framework at the core of the Palantir AI Platform.Lowe's is pioneering operational AI for its supply chain logistics with Palantir and NVIDIA. WASHINGTON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- GTC Washington, D.C. -- NVIDIA today announced a collaboration with Palantir Technologies Inc. to build a first-of-its-kind integrated technology stack for operational AI — including analytics capabilities, reference workflows, automation features and customizable, specialized AI agents — to accelerate and optimize complex enterprise and government systems.

    10/28/25 1:36:17 PM ET
    $NVDA
    Semiconductors
    Technology

    NVIDIA Announces DGX Cloud Lepton to Connect Developers to NVIDIA's Global Compute Ecosystem

    CoreWeave, Crusoe, Firmus, Foxconn, GMI Cloud, Lambda, Nebius Nscale, SoftBank Corp. and Yotta Data Services to Bring Tens of Thousands of GPUs to DGX Cloud Lepton MarketplaceNVIDIA Exemplar Clouds Raise the Performance Bar for NVIDIA Cloud Partners TAIPEI, Taiwan, May 19, 2025 (GLOBE NEWSWIRE) -- COMPUTEX -- NVIDIA today announced NVIDIA DGX Cloud Lepton™ — an AI platform with a compute marketplace that connects the world's developers building agentic and physical AI applications with tens of thousands of GPUs, available from a global network of cloud providers. To meet the demand for AI, NVIDIA Cloud Partners (NCPs) including CoreWeave, Crusoe, Firmus, Foxconn, GMI Cloud, Lambda, Nebi

    5/19/25 12:43:22 AM ET
    $NVDA
    Semiconductors
    Technology

    $EBS
    $NVDA
    $TSM
    Financials

    Live finance-specific insights

    View All

    Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year of 2025. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of

    2/12/26 9:02:20 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NVIDIA Sets Conference Call for Fourth-Quarter Financial Results

    SANTA CLARA, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- NVIDIA will host a conference call on Wednesday, February 25, at 2 p.m. PT (5 p.m. ET) to discuss its financial results for the fourth quarter and fiscal year 2026, which ended January 25, 2026. The call will be webcast live (in listen-only mode) on investor.nvidia.com. The company's prepared remarks will be followed by a Q&A session, which will be limited to questions from financial analysts and institutional investors. Ahead of the call, NVIDIA will provide written commentary on its fourth-quarter results from Colette Kress, the company's executive vice president and chief financial officer. This material will be posted to investor

    1/28/26 5:00:00 PM ET
    $NVDA
    Semiconductors
    Technology

    NVIDIA Announces Financial Results for Third Quarter Fiscal 2026

    Record revenue of $57.0 billion, up 22% from Q2 and up 62% from a year agoRecord Data Center revenue of $51.2 billion, up 25% from Q2 and up 66% from a year ago SANTA CLARA, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- NVIDIA (NASDAQ:NVDA) today reported record revenue for the third quarter ended October 26, 2025, of $57.0 billion, up 22% from the previous quarter and up 62% from a year ago. For the quarter, GAAP and non-GAAP gross margins were 73.4% and 73.6%, respectively. For the quarter, GAAP and non-GAAP earnings per diluted share were both $1.30. "Blackwell sales are off the charts, and cloud GPUs are sold out," said Jensen Huang, founder and CEO of NVIDIA. "Compute demand keeps acc

    11/19/25 4:20:00 PM ET
    $NVDA
    Semiconductors
    Technology

    $EBS
    $NVDA
    $TSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Emergent BioSolutions Inc.

    SC 13G - Emergent BioSolutions Inc. (0001367644) (Subject)

    11/13/24 4:00:18 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by NVIDIA Corporation

    SC 13G/A - NVIDIA CORP (0001045810) (Subject)

    11/12/24 10:32:12 AM ET
    $NVDA
    Semiconductors
    Technology

    Amendment: SEC Form SC 13G/A filed by Emergent BioSolutions Inc.

    SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)

    11/8/24 5:23:28 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care